Prognostic impact of PD-L1 expression in pN1 NSCLC

• Verfasst von: Eichhorn, Florian [VerfasserIn]
• Verfasst von: Kriegsmann, Mark [VerfasserIn]
• Verfasst von: Klotz, Laura Valentina [VerfasserIn]
• Verfasst von: Kriegsmann, Katharina [VerfasserIn]
• Verfasst von: Muley, Thomas [VerfasserIn]
• Verfasst von: Zgorzelski, Christiane [VerfasserIn]
• Verfasst von: Christopoulos, Petros [VerfasserIn]
• Verfasst von: Winter, Hauke [VerfasserIn]
• Verfasst von: Eichhorn, Martin E. [VerfasserIn]
• Titel: Prognostic impact of PD-L1 expression in pN1 NSCLC
• Titelzusatz: a retrospective single-center analysis
• Verf.angabe: Florian Eichhorn, Mark Kriegsmann, Laura V. Klotz, Katharina Kriegsmann, Thomas Muley, Christiane Zgorzelski, Petros Christopoulos, Hauke Winter and Martin E. Eichhorn
• E-Jahr: 2021
• Jahr: 23 April 2021
• Umfang: 13 S.
• Fussnoten: Gesehen am 23.06.2021
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2021
• Band/Heft Quelle: 13(2021), 9, Artikel-ID 2046, Seite 1-13
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers13092046
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1761093525

Abstract

Simple Summary - The analysis of prognostic biomarkers (e.g., PD-L1) helps to define treatment for lung cancer patients. To date, these markers have only been examined in metastatic or inoperable situations. We analyzed the PD-L1 expression-levels of tumors from 277 lung cancer patients that underwent curative intent surgery. PD-L1 was identified as a prognostic factor, depending on histologic subtype. - - Abstract - The programmed death-ligand 1 (PD-L1) plays a crucial role in immunomodulatory treatment concepts for end-stage non-small cell lung cancer (NSCLC). To date, its prognostic significance in patients with curative surgical treatment but regional nodal metastases, reflecting tumor spread beyond the primary site, is unclear. We evaluated the prognostic impact of PD-L1 expression in a surgical cohort of 277 consecutive patients with pN1 NSCLC on a tissue microarray. Patients with PD-L1 staining (clone SP263) on >1% of tumor cells were defined as PD-L1 positive. Tumor-specific survival (TSS) of the entire cohort was 64% at five years. Low tumor stage (p < 0.0001) and adjuvant therapy (p = 0.036) were identified as independent positive prognostic factors in multivariate analysis for TSS. PD-L1 negative patients had a significantly better survival following adjuvant chemotherapy than PD-L1 positive patients. The benefit of adjuvant therapy diminished in patients with PD-L1 expression in more than 10% of tumor cells. Stratification towards histologic subtype identified PD-L1 as a significant positive predictive factor for TSS after adjuvant therapy in patients with adenocarcinoma, but not squamous cell carcinoma. Routine PD-L1 assessment in curative intent treatment may help to identify patients with a better prognosis. Further research is needed to elucidate the predictive value of PD-L1 in an adjuvant setting.